Red Queen Bio

Red Queen Bio is an AI biosecurity company focused on developing defenses against AI-enabled biological threats. The company was spun out of HelixNano, a clinical-stage mRNA therapeutics company, by co-founders Nikolai and Hannu Rajaniemi. The founders have a history of working together for nearly a decade at HelixNano, where they collaborated with OpenAI and observed the potential for AI models in both therapeutic design and the creation of biological risks, which prompted the establishment of Red Queen Bio to build defensive infrastructure.

The firm's core mission is based on the concept of "defensive co-scaling," which aims to ensure that biological defenses advance at the same rate as AI capabilities. Red Queen Bio works with frontier AI labs to map potential biothreats and preemptively build medical countermeasures. Its pipeline utilizes advanced AI models, lab automation, and reinforcement learning, coupled with on-demand biologics manufacturing, to create a scalable defense system. As a Public Benefit Corporation, its governance structure prioritizes its mission over individual partnerships.

In November 2025, Red Queen Bio launched with a $15 million seed funding round led by OpenAI. Other investors include Cerberus Ventures, Fifty Years, and Halcyon Futures. The company's business model explores frameworks similar to catastrophic risk insurance and involves direct collaboration with AI labs, biopharma companies, and governments to create a sustainable financial model for biosecurity that is not solely reliant on government funding.

Keywords: AI biosecurity, biological threat defense, medical countermeasures, defensive co-scaling, biodefense, reinforcement learning, lab automation, public benefit corporation, AI risk mitigation, bioweapons prevention, biologics manufacturing, catastrophic risk insurance, biosecurity infrastructure, pandemic preparedness, synthetic biology defense, pathogen detection, AI safety, dual-use AI, frontier AI models, biothreat mapping